Product Description
ANK-700 is an investigational treatment for relapsing-remitting MS (RRMS). It encompasses a previously identified myelin antigen that is implicated in driving Multiple Sclerosis. (Sourced from: https://anokion.com/pipeline/multiple-sclerosis-study-of-ank-700-to-assess-safety-and-immune-tolerance/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Anokion
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple Sclerosis, Relapsing-Remitting
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04602390 |
MoveS-it | P1 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2024-04-23 |
47% |
2025-06-03 |
Patient Enrollment|Primary Endpoints|Treatments |